X-ray vendor Fischer Imaging continues to be plagued by a 50% drop in sales to OEMs. Hurt primarily by an ongoing decline in shipments of the Tilt-C tilting C-arm to GE Medical Systems, the Denver-based company reported a 31% drop in revenues in its
X-ray vendor Fischer Imaging continues to be plagued by a 50% drop in sales to OEMs. Hurt primarily by an ongoing decline in shipments of the Tilt-C tilting C-arm to GE Medical Systems, the Denver-based company reported a 31% drop in revenues in its second quarter (end-June).
Fischer posted revenues of $15.2 million, compared with $21.9 million in 1996. The company had a net loss of $1.4 million, compared with earnings of $946,000 in the same period in 1996.
While revenues were up 23% compared with the vendor's first-quarter results (SCAN 4/30/97), Fischer still remains sharply off last year's six-month pace. For the first six months of 1997, the company had revenues of $27.5 million, compared with $42 million in the same period in 1996. Fischer reported a net loss of $5.3 million in the first half, compared with net income of $2 million in 1996.
The news from Fischer wasn't all bad, however. Mammography system sales were up 42% in the second quarter, and the company has reduced its inventory in the first half of the year by $5.2 million. Fischer has $5.1 million in cash and remains essentially debt-free, according to Morgan Nields, chairman and CEO.
The company's primary R&D objective remains the completion of a clinical trial for its SenoScan full-field digital mammography system, which is now operating at five centers in the U.S. and Canada. Some of these sites are gathering data to support the company's 510(k) submission to the Food and Drug Administration, according to the company.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.